Cancer chemotherapy and somatic cell mutation.
The occurrence of a second neoplasm is one of the major obstacles in cancer chemotherapy. The elucidation of the genotoxic effects induced by anti-cancer drugs is considered to be helpful in identifying the degree of cancer risk. Numerous investigations on cancer patients after chemotherapy have demonstrated: (i) an increase in the in vivo somatic cell mutant frequency (Mf) at three genetic loci, including hypoxanthine-guanine phosphoribosyl-transferase (hprt), glycophorin A (GPA), and the T-cell receptor (TCR), and (ii) alterations in the mutational spectra of hprt mutants. However, the time required for and the degree of such changes are quite variable among patients even if they have received the same chemotherapy, suggesting the existence of underlying genetic factor(s). Accordingly, some cancer patients prior to chemotherapy as well as patients with cancer-prone syndrome have been found to show an elevated Mf. Based on the information obtained from somatic cell mutation assays, an individualized chemotherapy should be considered in order to minimize the risk of a second neoplasm.
Kubota
M
M
Department of Pediatrics, Faculty of Medicine, Kyoto University, Kawahara-cho 54, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan. Masaru.Kubota@ma2.seikyou.ne.jp
Lin
Y W
YW
Hamahata
K
K
Sawada
M
M
Koishi
S
S
Hirota
H
H
Wakazono
Y
Y
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics
D000970:Antineoplastic Agents